Sun Pharma’s arm settles case with Biofrontera
1st Dec 2021

Sun Pharmaceutical’s arm -- DUSA Pharmaceuticals Inc has reached settlement with Biofrontera to resolve a litigation over misappropriation of trade secrets and unfair practice, following which DUSA will receive $22.5 million (nearly Rs 170 crore).

Earlier, in 2018, DUSA Pharmaceuticals, Inc had filed a lawsuit against Biofrontera Inc., Biofrontera Bioscience GmbH, Biofrontera Pharma GmbH, and Biofrontera AG (together ‘Biofrontera’), in the United States District Court for the District of Massachusetts, alleging misappropriation of trade secrets, tortious interference of contract and unfair trade practices (the ‘Litigation’).

Sun Pharmaceutical is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.